Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Fuji Pharma Co., Ltd. (FUP) AI Stock Analysis

0 Followers
DE:FUP

Fuji Pharma Co., Ltd.

(Frankfurt:FUP)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Consistent Revenue GrowthFuji Pharma's ~17% revenue growth reflects sustained product demand and commercial execution in its prescription business. Durable top-line expansion supports reinvestment in R&D and manufacturing scale, underpinning multi-quarter growth prospects independent of short-term market swings.
Negative Factors
Rising LeverageAn increasing debt-to-equity trend raises financial risk and interest obligations, lowering buffer against revenue or margin shocks. Sustained leverage growth can constrain capital allocation, limit strategic flexibility, and amplify downside during cyclical or regulatory headwinds.

Fuji Pharma Co., Ltd. (FUP) vs. iShares MSCI Germany ETF (EWG)

-10%0%10%20%30%40%50%60%DE:FUP+19.42%EWG+9.86%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 277.06M
Dividend Yield
2.18%
Average Volume (3M)
―
Price to Earnings (P/E)
15.9
Beta (1Y)
0.36
Revenue Growth
8.84%
EPS Growth
-13.90%
Country
Germany
Employees
1,760
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Fuji Pharma Co., Ltd. Business Overview & Revenue Model

Company Description

Fuji Pharma Co., Ltd. is a pharmaceutical company that operates globally, focusing on the complete spectrum of drug development, from initial research and discovery through manufacturing and commercialization. Its comprehensive product line includes...

Fuji Pharma Co., Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:FUP against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
JP:4534JP:453468NeutralJPY 111.10B13.256.64%2.52%14.72%52.55%
JP:4577JP:457767NeutralJPY 38.11B12.20―3.05%-2.83%65.69%
JP:4886JP:488666NeutralJPY 52.08B12.92―3.34%―-7.20%
JP:4538JP:453864NeutralJPY 18.49B8.33―4.30%2.29%―
JP:4569JP:456952NeutralJPY 58.22B30.69―4.28%-4.71%-78.91%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

-20%0%20%40%DE:FUPJP:4534JP:4538JP:4569JP:4577JP:4886Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:FUP and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:FUPFuji Pharma Co., Ltd.10.201.5618.08%
JP:4534Mochida Pharmaceutical Co., Ltd.3275.00268.118.92%
JP:4538Fuso Pharmaceutical Industries,Ltd.2094.0053.682.63%
JP:4569KYORIN Pharmaceutical Co.,Ltd.1098.00-252.33-18.69%
JP:4577Daito Pharmaceutical Co., Ltd.1311.00119.7510.05%
JP:4886ASKA Pharmaceutical Holdings Co., Ltd.1948.00-35.23-1.78%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.